StreetAlpha.app
Home › Stocks › NAUT

Nautilus Biotechnology, Inc. (NAUT)

Healthcare
$2.36
▲ +12.38%
LAST CLOSE · NOV 17

Nautilus Biotechnology makes the Voyager platform, a system of instruments, consumables and software for measuring proteins in research. It last closed at $2.36 on Nov 17, up 12.38% on the day. The average 12-month price target from 2 analysts is $3.75 (+58.9% from the last close), with a high of $4.00 and a low of $3.50. In the past 30 days there were 1 dark pool print totaling $149K, the largest $149K.

AI Auto Pilots
Is NAUT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$58.6M
EPS (diluted)
−$0.46
Free cash flow
−$55.1M
Valuation
Market cap
$300.6M
127.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.5M
At Sep 30
Shareholder equity
$116.6M
Shares outstanding
127.4M
At Oct 22
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$50.3M−$50.3MFY2021FY2022: −$57.9M−$57.9MFY2022FY2023: −$63.7M−$63.7MFY2023FY2024: −$70.8M−$70.8MFY2024FY2025: −$59.0M−$59.0MFY2025

From NAUT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated NAUT in the past 90 days, not enough for a consensus
Average 12-month target
$3.75
▲ 58.9% upside

Based on 2 analysts who set a price target on NAUT in the past 90 days. The average target is $3.75, with a high of $4.00 and a low of $3.50, compared with the last close of $2.36.

Low $3.50Avg $3.75High $4.00
Blue marker: last close $2.36
Highest target$4.00
Average target$3.75
Lowest target$3.50
Latest rating changes
Roth CapitalInitiated
Sep 29Buy$3.50
Leerink PartnersInitiated
Sep 9Buy$4
DateFirmActionRatingPrice target
Sep 29Roth CapitalInitiatedBuy$3.50
Sep 9Leerink PartnersInitiatedBuy$4
Loading…

Technical Analysis

NAUT · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 10% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the Pivot at $2.31, and the nearest resistance the swing high (Jun 25) at $2.45.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 13.8%/day
Key levels
$4.3152 week high+82.6%
$2.5320 day average+7.2%
$2.49Pivot R1+5.5%
$2.45Swing high (Jun 25)+3.8%
$2.36Last close
$2.31Pivot−2.1%
$2.29Swing low (May 21)−3.0%
$2.19Pivot S1−7.2%
$2.13200 day average−9.7%
$1.9250 day average−18.6%
$1.59100 day average−32.6%
$0.8452 week low−64.4%
Indicators
RSI (14)51.62Middle of its rangeNeutral
MACD0.06Below its signal lineBearish
Stochastic18.9Near the bottom of its rangeOversold
ADX (14)25.4Trending up
Williams %R-74.1Oversold below −80, overbought above −20Neutral
CCI (20)-52.8Oversold below −100, overbought above 100Neutral
Rate of change+0.4%Change over 10 sessionsBullish
ATR (14)$0.33Typical daily range, 13.8% of price
MA 10Above
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for NAUT

What happened before

See how NAUT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NAUT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NAUT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NAUT in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$149K
Largest print
$149K
Loading…

NAUT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▲45 buying vs 35 selling
  • ▼Held by funds -5.6 pts
  • ▼Funds holding -6
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8793−6.5%
In funds' top 1001−100.0%
Held by funds33.8%39.4%−5.6 pts
New / increased10 / 3530 / 29−23.7%
Reduced / sold out19 / 1611 / 17+25.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NAUT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAUT is in one of them and how their past NAUT trades turned out.

NAUT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NAUT in an article yet. Here's the latest on the wider market.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company based in Seattle, Washington, that is developing tools for measuring proteins in biological samples. Its Voyager platform combines instruments, consumables and software for proteomics research, with the aim of counting protein and protein variant levels one molecule at a time. The company serves researchers and life science customers. For now it offers analysis services to a limited group of early access customers while it works toward broader commercial sales. Its technology is aimed at drug discovery, biomarker research and precision medicine.

Headquarters
Seattle, WA